M4R agonists have demonstrated positive effects on psychiatric and cognitive symptoms in patients with schizophrenia and related psychotic disorders, while reductions in M4R activation have been associated with hippocampal deficits thought to underlie the amnestic features of AD [82]. This evidence concerns the gene CHRM4 and psychotic disorder.